GlassScriptPhysician profile
Justin Baptist
NPI 1982095758
$22,887.08
in general payments reported to CMS, 2019-2025
15 companies · $7,450 in 2025
The $7,450 reported for 2025 was more than what 99% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2020: $150 · 2021: $115 · 2022: $115 · 2023: $7,724 · 2024: $7,036 · 2025: $7,450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $1,760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,450.00 |
| Food and Beverage | $1,760.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $21,722.03 | 2021-2025 | Dalvance, Teflaro, Mavyret |
| Allergan, INC. | $321.81 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $172.93 | 2019-2024 | Dificid, Zerbaxa, Delstrigo |
| Insmed, INC. | $124.83 | 2022-2025 | Arikayce, Brinsupri |
| Shionogi INC | $89.63 | 2023-2025 | Fetroja |
| Paratek Pharmaceuticals, INC. | $89.46 | 2023-2025 | Nuzyra |
| Philips North America LLC | $77.24 | 2020-2023 | |
| Viiv Healthcare Company | $67.72 | 2023-2025 | Cabenuva, Rukobia |
| La Jolla Pharmaceutical Company | $59.53 | 2025 | Zevtera, Xacduro |
| Cumberland Pharmaceuticals, INC. | $58.91 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $34.11 | 2025 | Vowst |
| Melinta Therapeutics, LLC | $27.31 | 2022 | |
| Ferring Pharmaceuticals INC. | $16.83 | 2023 | Rebyota |
| Vyera Pharmaceuticals, LLC | $12.95 | 2019 | |
| Theratechnologies INC. | $11.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Baptist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.